Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer

Stage III–IV non-small cell lung cancer (NSCLC) is a devastating disease characterized by a poor prognosis. NSCLC tumors carry genetic mutations, which can lead to the expression of altered protein sequences. Peptides originating from mutated proteins and bound to MHC molecules on the tumor cell sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Oosting, Linette T., Franke, Katka, Martin, Michael V., Kloosterman, Wigard P., Jamieson, Jennifer A., Glenn, Laura A., de Jager, Miranda W., van Zanten, Jacoba, Allersma, Derk P., Gareb, Bahez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322189/
https://www.ncbi.nlm.nih.gov/pubmed/35890409
http://dx.doi.org/10.3390/pharmaceutics14071515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322189/
https://www.ncbi.nlm.nih.gov/pubmed/35890409
http://dx.doi.org/10.3390/pharmaceutics14071515

Ejemplares similares